GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Radiopharm Theranostics Ltd (OTCPK:RDPTF) » Definitions » Shares Outstanding (Diluted Average)

Radiopharm Theranostics (Radiopharm Theranostics) Shares Outstanding (Diluted Average) : 343.28 Mil (As of Dec. 2023)


View and export this data going back to 2022. Start your Free Trial

What is Radiopharm Theranostics Shares Outstanding (Diluted Average)?

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. Radiopharm Theranostics's average diluted shares outstanding for the quarter that ended in Dec. 2023 was 343.28 Mil.


Radiopharm Theranostics Shares Outstanding (Diluted Average) Historical Data

The historical data trend for Radiopharm Theranostics's Shares Outstanding (Diluted Average) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Radiopharm Theranostics Shares Outstanding (Diluted Average) Chart

Radiopharm Theranostics Annual Data
Trend Jun22 Jun23
Shares Outstanding (Diluted Average)
198.51 323.82

Radiopharm Theranostics Semi-Annual Data
Dec21 Jun22 Dec22 Jun23 Dec23
Shares Outstanding (Diluted Average) 119.05 277.98 292.91 354.72 343.28

Radiopharm Theranostics Shares Outstanding (Diluted Average) Calculation

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. They have voting rights and represent ownership in the corporation by the person that holds the shares. They should be distinguished from treasury shares, which are shares held by the corporation itself, having no exercisable rights.

Shares outstanding can be calculated as either basic or fully diluted. The fully diluted shares outstanding count includes diluting securities, such as options, warrants or convertibles.

Please note: GuruFocus named Shares Outstanding (EOP) is the shares for that exact time point. It is usually used to calculate balance sheet related items, such as Book Value per Share, etc. While Shares Outstanding (Diluted Average) and Shares Outstanding (Basic Average) are the weighted average shares over a period of time (a year, a quarter, or so). They are usually used to calculate income statement or cashflow statement related items, such as Earnings per Share (Diluted), etc.


Radiopharm Theranostics  (OTCPK:RDPTF) Shares Outstanding (Diluted Average) Explanation

A company may buy back shares or issue shares in any fiscal period. If a company buys back shares, we should observe that the total number of shares decline. If the company issues new shares, the number of shares outstanding increases.


Be Aware

Usually the presence of treasury shares and a history of buyback are good indicators that company has competitive advantage. But studies have shown that companies usually buy back at wrong time. Buying back shares below its intrinsic value increases value for remaining shareholders. Buying back overvalued shares destroys value for existing shareholders.


Radiopharm Theranostics Shares Outstanding (Diluted Average) Related Terms

Thank you for viewing the detailed overview of Radiopharm Theranostics's Shares Outstanding (Diluted Average) provided by GuruFocus.com. Please click on the following links to see related term pages.


Radiopharm Theranostics (Radiopharm Theranostics) Business Description

Traded in Other Exchanges
Address
62 Lygon Street, Level 3, Carlton South, Melbourne, VIC, AUS, 3053
Radiopharm Theranostics Ltd is a Australian based clinical-stage radiotherapeutics company which is targeting cancer. The company has a pipeline of around four licensed platform technologies, with diagnostic and therapeutic applications in both pre-clinical and clinical stages of development. The company is engaged in research, development and commercialisation of health technologies.

Radiopharm Theranostics (Radiopharm Theranostics) Headlines

From GuruFocus

PIVALATE ACHIEVES POSITIVE PHASE 2 DATA IN BRAIN METS TRIAL

By PRNewswire PRNewswire 10-19-2022

RAD adds brain tumor technology to portfolio

By PRNewswire PRNewswire 06-30-2022

RAD adds brain tumor technology to portfolio

By PRNewswire PRNewswire 07-10-2022

RAD adds brain tumor technology to portfolio

By PRNewswire PRNewswire 06-10-2022

RAD adds brain tumor technology to portfolio

By PRNewswire PRNewswire 06-20-2022